title: Ertapenem compared to combination drug therapy for the treatment of postpartum endometritis after cesarean delivery.
abstract: OBJECTIVE
  Ertapenem is a broad spectrum carbapenem approved for the treatment of postpartum endometritis. Data regarding clinical outcomes after treatment with ertapenem for endometritis after cesarean delivery are limited. Our objectives were to compare clinical outcomes and cost of ertapenem versus a multi-drug regimen for treatment of endometritis after cesarean delivery.
  
  
  METHODS
  Retrospectively, patients with endometritis after cesarean delivery who were treated with ertapenem (group A) were compared to those treated with a combination regimen (group B). Mann-Whitney U and Fisher's Exact were used for statistical analysis with p value <0.05 considered statistically significant.
  
  
  RESULTS
  Sixty-three patients were included: 31 in group A and 32 in group B. Demographics and intrapartum characteristics did not differ. Number of administered doses (A: 3, B: 11.5 p < 0.0001), cost (A: $156.63, B: $54.48 p < 0.0001) and nursing time in minutes (A: 6.6, B: 25.3 p < 0.0001) were different between both groups. Wound complications were higher in group A, occurring in 7 patients compared to 1 patient in group B (p = 0.024).
  
  
  CONCLUSIONS
  Although time and number of administered doses were less in group A, given the high wound complication rate in patients treated with ertapenem, this drug may not be appropriate for all patients with endometritis after CD.
authors.affiliation: Department of Obstetrics, Gynecology and Women's Health, UMDNJ-New Jersey Medical School, Newark, NJ 07101, USA.
authors.forename: Kelecia R
authors.initials: KR
authors.lastname: Brown
authors.forename: Shauna F
authors.initials: SF
authors.lastname: Williams
authors.forename: Joseph J
authors.initials: JJ
authors.lastname: Apuzzio
mesh_terms: D000328:Adult; D000667:Ampicillin / Q000008:administration & dosage / Q000191:economics; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use; D002585:Cesarean Section / Q000009:adverse effects* / Q000534:rehabilitation; D002981:Clindamycin / Q000008:administration & dosage / Q000191:economics; D015331:Cohort Studies; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D004359:Drug Therapy, Combination / Q000191:economics; D004716:Endometritis / Q000188:drug therapy* / Q000209:etiology*; D000077727:Ertapenem; D005260:Female; D005839:Gentamicins / Q000008:administration & dosage / Q000191:economics; D006801:Humans; D007231:Infant, Newborn; D011181:Postnatal Care / Q000379:methods; D011247:Pregnancy; D011645:Puerperal Infection / Q000188:drug therapy* / Q000209:etiology; D012189:Retrospective Studies; D055815:Young Adult; D047090:beta-Lactams / Q000191:economics / Q000627:therapeutic use*
chemical_list: D000900:Anti-Bacterial Agents; D005839:Gentamicins; D047090:beta-Lactams; D002981:Clindamycin; D000667:Ampicillin; D000077727:Ertapenem